Strongbridge Biopharma (NASDAQ:SBBP) is scheduled to announce its earnings results before the market opens on Wednesday, July 31st. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Strongbridge Biopharma has set its FY 2019 guidance at EPS.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.09. The business had revenue of $4.34 million during the quarter, compared to the consensus estimate of $4.69 million. Strongbridge Biopharma had a net margin of 227.79% and a return on equity of 79.31%. On average, analysts expect Strongbridge Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Strongbridge Biopharma stock traded up $0.05 during mid-day trading on Tuesday, reaching $2.65. The company’s stock had a trading volume of 2,818 shares, compared to its average volume of 102,075. The stock has a market cap of $140.84 million, a P/E ratio of 8.57 and a beta of 0.85. The firm’s 50 day simple moving average is $3.03. Strongbridge Biopharma has a 12 month low of $2.50 and a 12 month high of $6.55.

A number of brokerages have commented on SBBP. BidaskClub upgraded shares of Zumiez from a “hold” rating to a “buy” rating in a research note on Friday, April 26th. TheStreet cut shares of YRC Worldwide from a “c” rating to a “d+” rating in a research note on Wednesday, May 15th. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Strongbridge Biopharma has a consensus rating of “Buy” and a consensus price target of $13.07.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

See Also: How to Invest in a Bull Market

Earnings History for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with's FREE daily email newsletter.